4582
SymBio Pharmaceuticals Limited
シンバイオ製薬
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Notes
- Consolidation basisConsolidated / Since Dec 2022
Key metrics
Revenue(thousand JPY)
Dec 2021
8,256,924
Dec 2022
10,008,338
Dec 2023
5,589,708
Dec 2024
2,452,912
Dec 2025
1,307,648
Operating profit(thousand JPY)
Dec 2021
1,016,001
Dec 2022
1,963,625
Dec 2023
-811,668
Dec 2024
-3,876,971
Dec 2025
-4,440,687
Operating profit margin(%)
Dec 2021
12.3
Dec 2022
19.62
Dec 2023
-14.52
Dec 2024
-158.06
Dec 2025
-339.59
Profit before tax(thousand JPY)
Dec 2021
1,001,331
Dec 2022
2,106,279
Dec 2023
-1,195,387
Dec 2024
-3,806,957
Dec 2025
-4,748,620
Profit(thousand JPY)
Dec 2021
2,032,203
Dec 2022
1,179,238
Dec 2023
-1,962,817
Dec 2024
-3,833,480
Dec 2025
-4,776,194
Total assets(thousand JPY)
Dec 2021
8,452,997
Dec 2022
10,433,347
Dec 2023
8,170,243
Dec 2024
4,968,333
Dec 2025
3,867,316
Cash and cash equivalents(thousand JPY)
Dec 2021
3,860,106
Dec 2022
6,282,554
Dec 2023
6,517,007
Dec 2024
3,963,580
Dec 2025
2,883,503
Cash flows from operating activities(thousand JPY)
Dec 2021
140,042
Dec 2022
1,614,241
Dec 2023
-194,685
Dec 2024
-3,416,518
Dec 2025
-4,575,568
Cash flows from investing activities(thousand JPY)
Dec 2021
-70,849
Dec 2022
-47,127
Dec 2023
-376,696
Dec 2024
-3,955
Dec 2025
-75,916
Cash flows from financing activities(thousand JPY)
Dec 2021
-71,922
Dec 2022
627,985
Dec 2023
680,160
Dec 2024
708,472
Dec 2025
3,621,610
Return on equity(%)
Dec 2021
39.6
Dec 2022
14.6
Dec 2023
-
Dec 2024
-
Dec 2025
-
Equity ratio(%)
Dec 2021
73.7
Dec 2022
77.6
Dec 2023
84.9
Dec 2024
78.1
Dec 2025
23.9
Earnings per share(JPY per share)
Dec 2021
53.04
Dec 2022
30.2
Dec 2023
-49.19
Dec 2024
-85
Dec 2025
-95.12
Net assets per share(JPY per share)
Dec 2021
162.26
Dec 2022
204.83
Dec 2023
164.32
Dec 2024
84.66
Dec 2025
15.54
Dividend per share(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.